Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

The impact of common polymorphisms in CETP and ABCA1 genes with the risk of coronary artery disease in Saudi Arabians.

Cyrus C, Vatte C, Al-Nafie A, Chathoth S, Al-Ali R, Al-Shehri A, Akhtar MS, Almansori M, Al-Muhanna F, Keating B, Al-Ali A.

Hum Genomics. 2016 Mar 2;10:8. doi: 10.1186/s40246-016-0065-3.

2.

Large animal models of cardiovascular disease.

Tsang HG, Rashdan NA, Whitelaw CB, Corcoran BM, Summers KM, MacRae VE.

Cell Biochem Funct. 2016 Apr;34(3):113-32. doi: 10.1002/cbf.3173. Epub 2016 Feb 24. Review.

PMID:
26914991
3.

Evaluation of CETP activity in vivo under non-steady-state conditions: influence of anacetrapib on HDL-TG flux.

McLaren DG, Previs SF, Phair RD, Stout SJ, Xie D, Chen Y, Salituro GM, Xu SS, Castro-Perez JM, Opiteck GJ, Akinsanya KO, Cleary MA, Dansky HM, Johns DG, Roddy TP.

J Lipid Res. 2016 Mar;57(3):398-409. doi: 10.1194/jlr.M063842. Epub 2015 Dec 9.

PMID:
26658238
4.

Influence of Sorghum Kafirin on Serum Lipid Profile and Antioxidant Activity in Hyperlipidemic Rats (In Vitro and In Vivo Studies).

Ortíz Cruz RA, Cárdenas López JL, González Aguilar GA, Astiazarán García H, Gorinstein S, Canett Romero R, Robles Sánchez M.

Biomed Res Int. 2015;2015:164725. doi: 10.1155/2015/164725. Epub 2015 Oct 26.

5.

AIBP: A Novel Molecule at the Interface of Cholesterol Transport, Angiogenesis, and Atherosclerosis.

Zhu L, Fang L.

Methodist Debakey Cardiovasc J. 2015 Jul-Sep;11(3):160-5. doi: 10.14797/mdcj-11-3-160.

6.

Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors.

Cannady EA, Wang MD, Friedrich S, Rehmel JL, Yi P, Small DS, Zhang W, Suico JG.

Pharmacol Res Perspect. 2015 Oct;3(5):e00179. doi: 10.1002/prp2.179. Epub 2015 Oct 12.

7.
8.

Cholesterol Metabolism in CKD.

Reiss AB, Voloshyna I, De Leon J, Miyawaki N, Mattana J.

Am J Kidney Dis. 2015 Dec;66(6):1071-82. doi: 10.1053/j.ajkd.2015.06.028. Epub 2015 Sep 1. Review.

PMID:
26337134
9.

CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome.

Cannady EA, Suico JG, Wang MD, Friedrich S, Rehmel JR, Nicholls SJ, Krueger KA.

Br J Clin Pharmacol. 2015 Dec;80(6):1388-98. doi: 10.1111/bcp.12730. Epub 2015 Oct 27.

PMID:
26264702
10.

Defective triglyceride biosynthesis in CETP-deficient SW872 cells.

Greene DJ, Izem L, Morton RE.

J Lipid Res. 2015 Sep;56(9):1669-78. doi: 10.1194/jlr.M056481. Epub 2015 Jul 22.

PMID:
26203075
11.

Unsaturated fatty acids supplementation reduces blood lead level in rats.

Skoczyńska A, Wojakowska A, Nowacki D, Bobak Ł, Turczyn B, Smyk B, Szuba A, Trziszka T.

Biomed Res Int. 2015;2015:189190. doi: 10.1155/2015/189190. Epub 2015 May 14.

12.

Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?

Mani P, Rohatgi A.

Curr Atheroscler Rep. 2015 Aug;17(8):43. doi: 10.1007/s11883-015-0521-x. Review.

PMID:
26048725
13.

A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion.

Temel RE, Brown JM.

Trends Pharmacol Sci. 2015 Jul;36(7):440-51. doi: 10.1016/j.tips.2015.04.002. Epub 2015 Apr 27. Review.

PMID:
25930707
14.

New Diterpenes from Cultures of the Fungus Engleromyces goetzii and Their CETP Inhibitory Activity.

Wang Y, Zhang L, Wang F, Li ZH, Dong ZJ, Liu JK.

Nat Prod Bioprospect. 2015 Apr 8. [Epub ahead of print]

15.

Enhancing reverse cholesterol transport/raising HDL cholesterol: new options for prevention and treatment of cardiovascular disease.

Jukema JW, Lenselink M, de Grooth GJ, Boekholdt SM, Liem AH, Kuivenhoven JA, Kastelein JJ.

Neth Heart J. 2004 Nov;12(11):491-496. Review.

16.

New loci and coding variants confer risk for age-related macular degeneration in East Asians.

Cheng CY, Yamashiro K, Chen LJ, Ahn J, Huang L, Huang L, Cheung CM, Miyake M, Cackett PD, Yeo IY, Laude A, Mathur R, Pang J, Sim KS, Koh AH, Chen P, Lee SY, Wong D, Chan CM, Loh BK, Sun Y, Davila S, Nakata I, Nakanishi H, Akagi-Kurashige Y, Gotoh N, Tsujikawa A, Matsuda F, Mori K, Yoneya S, Sakurada Y, Iijima H, Iida T, Honda S, Lai TY, Tam PO, Chen H, Tang S, Ding X, Wen F, Lu F, Zhang X, Shi Y, Zhao P, Zhao B, Sang J, Gong B, Dorajoo R, Yuan JM, Koh WP, van Dam RM, Friedlander Y, Lin Y, Hibberd ML, Foo JN, Wang N, Wong CH, Tan GS, Park SJ, Bhargava M, Gopal L, Naing T, Liao J, Ong PG, Mitchell P, Zhou P, Xie X, Liang J, Mei J, Jin X, Saw SM, Ozaki M, Mizoguchi T, Kurimoto Y, Woo SJ, Chung H, Yu HG, Shin JY, Park DH, Kim IT, Chang W, Sagong M, Lee SJ, Kim HW, Lee JE, Li Y, Liu J, Teo YY, Heng CK, Lim TH, Yang SK, Song K, Vithana EN, Aung T, Bei JX, Zeng YX, Tai ES, Li XX, Yang Z, Park KH, Pang CP, Yoshimura N, Wong TY, Khor CC.

Nat Commun. 2015 Jan 28;6:6063. doi: 10.1038/ncomms7063. Erratum in: Nat Commun. 2015;6:6817.

17.

Overexpression of full-length cholesteryl ester transfer protein in SW872 cells reduces lipid accumulation.

Izem L, Greene DJ, Bialkowska K, Morton RE.

J Lipid Res. 2015 Mar;56(3):515-25. doi: 10.1194/jlr.M053678. Epub 2015 Jan 14.

18.

Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease.

Proitsi P, Kim M, Whiley L, Pritchard M, Leung R, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Sham P, Lovestone S, Powell JF, Dobson RJ, Legido-Quigley C.

Transl Psychiatry. 2015 Jan 13;5:e494. doi: 10.1038/tp.2014.127.

19.

Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.

Mabuchi H, Nohara A, Inazu A.

Mol Cells. 2014 Nov;37(11):777-84. doi: 10.14348/molcells.2014.0265. Epub 2014 Nov 6. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk